Recent analyses have shown that human cells transcribe almost their entire genomes, implying the existence of a huge mass of ncRNAs. At the present, microRNAs are the most investigated regulative non-coding RNAs. Several studies have demonstrated that microRNAs play a crucial role in hematopoietic differentiation and hematological malignancies, including acute myeloid leukemia (AML). Aberrant expression of microRNAs has been associated with specific genetic abnormalities and clinical outcome of patients with AML. In addition, since microRNAs can function as either oncogenes or tumor suppressor genes, the potential of using these molecules as therapeutic targets opens up new opportunities in the future of AML therapy. The recent demonstration that other regulatory ncRNAs, in addition to microRNAs, are involved in hematopoietic cell differentiation and diseases, suggests that they may also have a biological relevance in AML. This paper will describe the role of ncRNAs in AML and discuss the expectations for the use of ncRNAs in diagnosis, prognosis, and therapy of AML.
Noncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical Players / Fatica, Alessandro. - In: SCIENTIFICA. - ISSN 2090-908X. - ELETTRONICO. - 2012(2012), pp. 1-10.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Noncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical Players|
|Data di pubblicazione:||2012|
|Citazione:||Noncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical Players / Fatica, Alessandro. - In: SCIENTIFICA. - ISSN 2090-908X. - ELETTRONICO. - 2012(2012), pp. 1-10.|
|Appartiene alla tipologia:||01a Articolo in rivista|